JP2017525364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525364A5 JP2017525364A5 JP2017509626A JP2017509626A JP2017525364A5 JP 2017525364 A5 JP2017525364 A5 JP 2017525364A5 JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017525364 A5 JP2017525364 A5 JP 2017525364A5
- Authority
- JP
- Japan
- Prior art keywords
- mesenchymal stem
- stem cell
- genetically modified
- promoter
- modified mesenchymal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 38
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 102000004127 Cytokines Human genes 0.000 claims 15
- 108090000695 Cytokines Proteins 0.000 claims 15
- 238000011398 antitumor immunotherapy Methods 0.000 claims 14
- 230000028993 immune response Effects 0.000 claims 14
- 230000004936 stimulating effect Effects 0.000 claims 14
- 108010012236 Chemokines Proteins 0.000 claims 9
- 102000019034 Chemokines Human genes 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 9
- 108010002586 Interleukin-7 Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000003623 enhancer Substances 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 5
- 108010065805 Interleukin-12 Proteins 0.000 claims 5
- 102100030704 Interleukin-21 Human genes 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 5
- 108010074108 interleukin-21 Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims 2
- -1 CCL22 Proteins 0.000 claims 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000035605 chemotaxis Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 238000011133 mesenchymal stem cell therapy Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14181283 | 2014-08-18 | ||
| EP14181283.4 | 2014-08-18 | ||
| PCT/EP2015/068942 WO2016026854A2 (en) | 2014-08-18 | 2015-08-18 | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525364A JP2017525364A (ja) | 2017-09-07 |
| JP2017525364A5 true JP2017525364A5 (enExample) | 2018-09-20 |
| JP6712993B2 JP6712993B2 (ja) | 2020-06-24 |
Family
ID=51352460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509626A Active JP6712993B2 (ja) | 2014-08-18 | 2015-08-18 | 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170239297A1 (enExample) |
| EP (2) | EP3656387A3 (enExample) |
| JP (1) | JP6712993B2 (enExample) |
| CN (1) | CN106659742B (enExample) |
| AU (1) | AU2015306231B2 (enExample) |
| CA (1) | CA2956987C (enExample) |
| IL (1) | IL250388B (enExample) |
| WO (1) | WO2016026854A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| MX387323B (es) * | 2014-02-19 | 2025-03-18 | Merck Patent Gmbh | Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer. |
| KR20190003456A (ko) * | 2016-04-01 | 2019-01-09 | 아프세스 게엠베하 & 씨오. 카게 | 면역치료의 항-종양 활성을 높이기 위한 중간엽 줄기세포 |
| WO2018071295A1 (en) * | 2016-10-10 | 2018-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inducible production of anti-inflammatory cytokines |
| CN108148862B (zh) | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| WO2018170390A1 (en) * | 2017-03-17 | 2018-09-20 | Senti Biosciences, Inc. | Immunomodulating cell circuits |
| RU2019133327A (ru) * | 2017-04-07 | 2021-05-07 | Сината Терапьютикс Лимитед | Способ лечения побочного эффекта терапии Т-клетками с химерными антигенными рецепторами (CAR) |
| WO2018191619A1 (en) * | 2017-04-13 | 2018-10-18 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN107184603B (zh) * | 2017-06-01 | 2020-06-30 | 刘未斌 | 一种治疗肿瘤的药物组合 |
| CN107184602B (zh) * | 2017-06-01 | 2020-06-30 | 刘未斌 | 一种治疗肿瘤的药物组合 |
| JP2020523400A (ja) * | 2017-06-16 | 2020-08-06 | サイナータ セラピューティクス リミテッド | 免疫療法の副作用を治療するための方法 |
| WO2019067491A1 (en) * | 2017-09-29 | 2019-04-04 | Oncocyclist, Inc. | COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION |
| US12016882B2 (en) | 2017-11-22 | 2024-06-25 | The Brigham And Women's Hospital, Inc. | Method of treating glioblastoma multiforme |
| IL264068B2 (en) | 2018-01-05 | 2023-07-01 | Great Novel Therapeutics Biotech & Medicals Corp | Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells |
| US20210163872A1 (en) * | 2018-01-12 | 2021-06-03 | Rutgers, The State University Of New Jersey | Cell Reprogramming Therapy |
| BR112020010536A2 (pt) | 2018-01-25 | 2020-12-01 | I-Mab Biopharma Us Limited | molécula de fusão, proteína e célula isoladas, composição, e, método para tratar um câncer |
| JP2021512950A (ja) * | 2018-02-02 | 2021-05-20 | エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． | 新規なワクチンの免疫補助剤 |
| EP3768842A4 (en) * | 2018-03-21 | 2021-12-29 | China Medical University | Engineering stem cells for cancer therapy |
| CN108864288A (zh) * | 2018-04-26 | 2018-11-23 | 上海怡豪生物科技有限公司 | 乳腺癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN110527696A (zh) * | 2018-06-13 | 2019-12-03 | 中山大学 | 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用 |
| CN121622884A (zh) * | 2018-07-06 | 2026-03-10 | 浙江生创精准医疗科技有限公司 | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 |
| WO2020046766A1 (en) * | 2018-08-26 | 2020-03-05 | Oaiscell Biotechnologies | Method for treating glioblastoma |
| WO2020057641A1 (zh) * | 2018-09-20 | 2020-03-26 | 科济生物医药（上海）有限公司 | 表达有趋化因子的细胞及用途 |
| US20210338729A1 (en) * | 2018-10-12 | 2021-11-04 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2019359890B2 (en) * | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN109593725A (zh) * | 2018-12-25 | 2019-04-09 | 河北生命原点生物科技有限公司 | 一种重组间充质干细胞及其应用 |
| KR20210139246A (ko) * | 2019-02-14 | 2021-11-22 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 면역 세포 효력을 검정하기 위한 원형질막 입자, 리포솜 및 엑소좀의 용도 |
| CN109762820B (zh) * | 2019-02-18 | 2020-07-28 | 河北佑仁生物科技有限公司 | 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用 |
| WO2020205969A1 (en) * | 2019-04-02 | 2020-10-08 | The General Hospital Corporation | Methods to enhance t cell regeneration |
| CN115851605A (zh) * | 2019-04-18 | 2023-03-28 | 上海交通大学 | 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法 |
| CN111139222B (zh) * | 2019-05-30 | 2020-12-29 | 北京双因生物科技有限公司 | 一种重组间充质干细胞及其制备方法和用途 |
| EP4556072A3 (en) * | 2019-08-23 | 2025-06-11 | Orbsen Therapeutics Limited | Compositions for monocyte and macrophage polarization and methods of use |
| EP4127195A4 (en) * | 2020-03-26 | 2024-12-11 | Agency for Science, Technology and Research | A method and system for introducing one or more exogenous substances into an immune cell |
| US20230227847A1 (en) * | 2020-05-27 | 2023-07-20 | Universität Zürich | Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia |
| JP7758370B2 (ja) * | 2020-07-16 | 2025-10-22 | チャンジェン セラピューティクス （シャンハイ） カンパニー リミテッド | 間葉系幹細胞によるケモカインおよびサイトカイン送達を標的とする免疫療法 |
| EP4229182A1 (en) * | 2020-10-16 | 2023-08-23 | Fundació Centre de Regulació Genòmica | Therapy for degenerative disease and tissue damage |
| CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
| CN114426953A (zh) * | 2020-10-29 | 2022-05-03 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-12的多能干细胞衍生物及应用 |
| CN114717232A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用 |
| WO2023274355A1 (zh) * | 2021-07-02 | 2023-01-05 | 上海交通大学 | 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤 |
| IL312434A (en) * | 2021-11-01 | 2024-06-01 | Mam Holdings Of West Florida L L C | Mesenchymal stem cells for the prevention and targeted treatment of cancer and other diseases |
| CN114480413B (zh) * | 2022-01-14 | 2022-11-04 | 北京贝来生物科技有限公司 | 一种活化肿瘤免疫应答的基因修饰干细胞制备方法 |
| CN115463155B (zh) * | 2022-11-01 | 2023-05-23 | 卡瑞济(北京)生命科技有限公司 | 间充质干细胞的用途 |
| CN117503952B (zh) * | 2022-11-24 | 2025-09-16 | 中国药科大学 | 一种基于血小板的免疫激活系统及其制备方法和应用 |
| WO2024137869A2 (en) * | 2022-12-20 | 2024-06-27 | City Of Hope | Stem cells for delivery of oncolytic viruses |
| US20250333700A1 (en) * | 2024-02-28 | 2025-10-30 | Gene Solutions Joint Stock Company | Modified k562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production |
| WO2026069312A1 (en) | 2024-09-24 | 2026-04-02 | Yeda Research And Development Co. Ltd. | Immune cells expressing an inducible therapeutic agent and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005531507A (ja) | 2002-03-02 | 2005-10-20 | ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法 |
| WO2005007176A1 (ja) * | 2003-06-27 | 2005-01-27 | Renomedix Institute Inc. | 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬 |
| EP1640898A4 (en) * | 2003-06-27 | 2011-01-12 | Nc Medical Res Inc | SELF-CELL DELIVERY SUPPORT SYSTEM FOR MEDICAL CARE, SELF-CELL DELIVERY-SUPPORT FINANCIAL SYSTEM FOR MEDICAL SERVICES AND METHOD THEREFOR |
| US20050002904A1 (en) | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| DK1799236T3 (da) * | 2004-09-10 | 2012-09-03 | Cognate Therapeutics Inc | Leverstromaceller til forebyggelse og behandling af immunresponser ved transplantation |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| WO2008150368A1 (en) * | 2007-05-24 | 2008-12-11 | Apceth Gmbh & Co. Kg | Cd34 stem cell-related methods and compositions |
| EP2019134A1 (en) | 2007-07-26 | 2009-01-28 | Vision 7 GmbH | Gene therapy of chronic granulomatous disease |
| RU2539099C2 (ru) * | 2009-04-13 | 2015-01-10 | Апцет Гмбх Унд Ко.Кг | Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей |
| AU2010341703B2 (en) * | 2009-12-08 | 2016-01-21 | The Board Of Trustees Of The University Of Illinois | Stem cell immune modulation methods of use and apparatus |
| CN101974485A (zh) * | 2010-11-12 | 2011-02-16 | 苏州大学 | 具有最佳迁移能力的间充质干细胞的制备方法及其应用 |
| US9101597B2 (en) | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
| WO2015035235A1 (en) * | 2013-09-06 | 2015-03-12 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Compositions and methods for increasing mesenchymal stromal cell migration to tumors |
| WO2015112626A1 (en) * | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| WO2016146819A1 (en) * | 2015-03-18 | 2016-09-22 | Apceth Gmbh & Co. Kg | Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells |
-
2015
- 2015-08-18 WO PCT/EP2015/068942 patent/WO2016026854A2/en not_active Ceased
- 2015-08-18 AU AU2015306231A patent/AU2015306231B2/en not_active Ceased
- 2015-08-18 EP EP19205297.5A patent/EP3656387A3/en not_active Withdrawn
- 2015-08-18 US US15/504,554 patent/US20170239297A1/en not_active Abandoned
- 2015-08-18 CA CA2956987A patent/CA2956987C/en active Active
- 2015-08-18 CN CN201580045089.6A patent/CN106659742B/zh active Active
- 2015-08-18 JP JP2017509626A patent/JP6712993B2/ja active Active
- 2015-08-18 EP EP15759667.7A patent/EP3182984B1/en active Active
-
2017
- 2017-02-01 IL IL250388A patent/IL250388B/en active IP Right Grant
-
2020
- 2020-01-28 US US16/774,495 patent/US11464806B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525364A5 (enExample) | ||
| Dobrzanski | Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy | |
| Brempelis et al. | Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses | |
| Zhang et al. | Interplay between inflammatory tumor microenvironment and cancer stem cells | |
| US11464806B2 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| Xie et al. | The role of CD4+ T cells in tumor and chronic viral immune responses | |
| Alpdogan et al. | IL-7 and IL-15: therapeutic cytokines for immunodeficiency | |
| Yuan et al. | The roles of tissue-resident memory T cells in lung diseases | |
| Ellyard et al. | Th2‐mediated anti‐tumour immunity: friend or foe? | |
| Mitchell et al. | Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells | |
| Dieu‐Nosjean et al. | Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers | |
| Stoycheva et al. | IFN-γ regulates CD8+ memory T cell differentiation and survival in response to weak, but not strong, TCR signals | |
| Hervas-Stubbs et al. | CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy | |
| JP2019509715A5 (enExample) | ||
| HK1257460A1 (zh) | 用於免疫疗法的巨噬细胞的遗传工程 | |
| Ogata et al. | Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming | |
| JP2018526450A5 (enExample) | ||
| JP2018528774A5 (enExample) | ||
| JP2012504959A5 (enExample) | ||
| JP2019536457A5 (enExample) | ||
| Kagoya | Cytokine signaling in chimeric antigen receptor T-cell therapy | |
| WO2018183169A4 (en) | Ank and il-12 compositions and methods | |
| AU2018277294A1 (en) | Oncolytic virus and method | |
| Willemen et al. | Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions | |
| Kokaji et al. | IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells |